171 related articles for article (PubMed ID: 22541932)
1. Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration.
Kim YM; Kim JH; Koh HJ
Am J Ophthalmol; 2012 Jul; 154(1):164-173.e1. PubMed ID: 22541932
[TBL] [Abstract][Full Text] [Related]
2. Association between foveal microstructure and visual outcome in age-related macular degeneration.
Shin HJ; Chung H; Kim HC
Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
[TBL] [Abstract][Full Text] [Related]
3. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.
Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N
Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745
[TBL] [Abstract][Full Text] [Related]
4. Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion.
Shin HJ; Chung H; Kim HC
Acta Ophthalmol; 2011 Feb; 89(1):e35-40. PubMed ID: 21155986
[TBL] [Abstract][Full Text] [Related]
5. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
6. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration.
Sayanagi K; Sharma S; Kaiser PK
Br J Ophthalmol; 2009 May; 93(5):622-6. PubMed ID: 19208677
[TBL] [Abstract][Full Text] [Related]
7. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
[TBL] [Abstract][Full Text] [Related]
9. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
10. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
[TBL] [Abstract][Full Text] [Related]
13. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration.
Kwon YH; Lee DK; Kim HE; Kwon OW
Korean J Ophthalmol; 2014 Oct; 28(5):386-92. PubMed ID: 25276080
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
16. Restored photoreceptor outer segment and visual recovery after macular hole closure.
Sano M; Shimoda Y; Hashimoto H; Kishi S
Am J Ophthalmol; 2009 Feb; 147(2):313-318.e1. PubMed ID: 18835472
[TBL] [Abstract][Full Text] [Related]
17. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
18. Integrity of foveal photoreceptor layer in central retinal vein occlusion.
Ota M; Tsujikawa A; Kita M; Miyamoto K; Sakamoto A; Yamaike N; Kotera Y; Yoshimura N
Retina; 2008; 28(10):1502-8. PubMed ID: 18997611
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of preoperative disrupted inner/outer segment junctions assessed using spectral-domain optical coherence tomography in patients with idiopathic epiretinal membrane.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Ophthalmologica; 2012; 228(4):222-8. PubMed ID: 22948332
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
